GlassScriptPhysician profile
Brittany Williams
NPI 1174211783
$3,929.67
in general payments reported to CMS, 2019-2025
27 companies · $2,395 in 2025
The $2,395 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $82.59 · 2024: $1,452 · 2025: $2,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,930.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,929.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,237.73 | 2024-2025 | |
| Biogen, INC. | $567.58 | 2024-2025 | Vumerity, Tysabri, Avonex |
| Novartis Pharmaceuticals Corporation | $291.80 | 2024-2025 | |
| Argenx US, INC. | $264.42 | 2024-2025 | Vyvgart Hytrulo |
| Takeda Pharmaceuticals U.S.A., INC. | $207.41 | 2024-2025 | Hyqvia |
| Lilly USA, LLC | $198.47 | 2024-2025 | Amyvid, Kisunla |
| Pfizer INC. | $188.10 | 2024-2025 | |
| Lundbeck LLC | $168.39 | 2024-2025 | Vyepti, Rexulti |
| Neurocrine Biosciences, INC. | $151.74 | 2024-2025 | Ingrezza |
| Ucb, INC. | $81.74 | 2025 | Bimzelx, Fintepla |
| Kyowa Kirin, INC. | $74.22 | 2024 | Nourianz |
| Endo Pharmaceuticals INC. | $58.27 | 2023 | Xiaflex, Aveed |
| Teva Pharmaceuticals USA, INC. | $56.29 | 2024-2025 | Austedo Xr, Austedo Xr |
| Si-Bone, INC. | $50.55 | 2024-2025 | |
| Eisai INC. | $45.85 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $45.17 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Tg Therapeutics, INC. | $41.84 | 2024 | |
| Genzyme Corporation | $30.37 | 2025 | |
| Neurelis, INC. | $26.36 | 2024 | Valtoco |
| Azurity Pharmaceuticals, INC. | $24.56 | 2025 | Zonisade |
| Halozyme INC | $24.32 | 2023 | |
| Janssen Biotech, INC. | $16.98 | 2025 | Tremfya |
| Inspire Medical Systems, INC. | $16.78 | 2025 | Inspire |
| Otsuka America Pharmaceutical, INC. | $16.25 | 2024 | Rexulti |
| Sumitomo Pharma America, INC. | $16.05 | 2024 | Aptiom |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.93 | 2024 | Lifevest |
| Emd Serono, INC. | $13.50 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.